Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Efficacy of roflumilast in the frequent exacerbation COPD phenotype Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Comparative effectiveness of add-on omalizumab for the treatment of severe persistent asthma between current and former smokers vs. non-smokers Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD Source: International Congress 2014 – Markers Year: 2014
Association of β2 -adrenoreceptor genotypes with prevention of COPD exacerbations by tiotropium or salmeterol in the POET-COPD® trial Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006
Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006
Airway and systemic inflammation profile in current smokers controls, COPD current smokers and COPD ex-smokers Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Effects of roflumilast in highly symptomatic COPD patients Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care Year: 2012
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use Source: Eur Respir J 2004; 24: Suppl. 48, 289s Year: 2004
Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE) Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
Restoring corticosteroid sensitivity in COPD and smokers with asthma Source: Annual Congress 2008 - Smokers with asthma versus COPD: differences and similarities Year: 2008
Effects of tiotropium on lung function in current smokers and never smokers with asthma Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015